Samsung Biologics Achieves Top ESG Rating: What This Means for Investors in 2026
AI 요약 정보
- Samsung Biologics earns Sustainalytics' Negligible rating
- Samsung Biologics ranks fourth among 842 global drugmakers
- Emissions down vs. 2023: Scope 1-2 9%, Scope 3 6.4%